Effect of Feiyiliu Mixture on Prognosis of Patients with Middle and Advanced Squamous Cell Carcinoma of Lung

Xian-tao LIU; Xin ZHENG

doi:10.13422/j.cnki.syfjx.20200131

您当前的位置：

首页 >

文章列表页 >

Effect of Feiyiliu Mixture on Prognosis of Patients with Middle and Advanced Squamous Cell Carcinoma of Lung

Clinic | 更新时间：2021-02-09

- Effect of Feiyiliu Mixture on Prognosis of Patients with Middle and Advanced Squamous Cell Carcinoma of Lung
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 8, Pages: 118-123(2020)
- 作者机构：
  
  1.山东中医药大学　附属医院，济南　 250011
  2.山东中医药大学，济南　 250014
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20200131
  CLC： R273; R734; R246.5; R289
- Received：12 September 2019，
  
  Published Online：21 October 2019，
  
  Published：20 April 2020
- 稿件说明：
移动端阅览
Xian-tao LIU, Xin ZHENG. Effect of Feiyiliu Mixture on Prognosis of Patients with Middle and Advanced Squamous Cell Carcinoma of Lung[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(8): 118-123.
DOI：

Xian-tao LIU, Xin ZHENG. Effect of Feiyiliu Mixture on Prognosis of Patients with Middle and Advanced Squamous Cell Carcinoma of Lung[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(8): 118-123. DOI： 10.13422/j.cnki.syfjx.20200131.

摘要

目的：

评价肺抑瘤合剂辅助化疗和免疫支持对Ⅲb，Ⅳ期肺鳞状细胞癌(SQCC)患者无进展生存期(PFS)，生存率的影响及对外周血肿瘤标志物和细胞因子的干预效果。

方法：

将132例患者随机按数字表法分为对照组和观察组各66例，均给予盐酸吉西他滨＋顺铂的GP方案，替代方案为紫杉醇＋顺铂，并给予注射用胸腺肽。观察组同期口服肺抑瘤合剂，对照组同期口服肺抑瘤合剂模拟药。两组患者均连续治疗4个周期。随访记录PFS和12个月生存率，进行治疗前后欧洲生命质量协作组癌症核心量表(EORTC QLQ-C30)评价；检测治疗前后CD3

＋

，CD4

＋

，CD8

＋

，CD4

＋

/CD8

＋

水平，检测治疗前后细胞角蛋白19片段21-1(CYFRA21-1)，鳞状细胞癌抗原(SCC)，糖抗原125(CA125)，血管内皮生长因子(VEGF)，基质金属蛋白酶-2(MMP-2)和MMP-9；进行治疗前后实体瘤大小的评价。

结果：

观察组实体瘤疗效临床缓解率为(35/66)53.03%，高于对照组的(23/66)34.85%(

＝4.286，

0.05)；观察组PFS为9.8个月(95% CI，4.58～22.37)，长于对照组的5.7个月(95% CI，4.69～20.41)(

0.05)；观察组12个月的生存率为(30/36)45.45%，高于对照组的(18/48)27.27%(

＝4.714，

0.05)；观察组躯体功能、社会功能和整体生活质量评分均高于对照组(

0.01)，疲乏、恶心呕吐、食欲丧失、便秘、腹泻评分均低于对照组(

0.01)；观察组CD3

＋

，CD4

＋

水平和CD4

＋

/CD8

＋

均高于对照组(

0.05)，CD8

＋

低于对照组(

0.05)；观察组CYFRA21-1，SCC，CA125，VEGF，MMP-2和MMP-9水平均低于对照组(

0.01)。

结论：

采用肺抑瘤合剂配合化疗和免疫支持治疗Ⅲb，Ⅳ期SQCC患者可延长患者PFS，提高生存率，能稳定免疫功能，提高生活质量，并能抑制CYFRA21-1等肿瘤标志物和VEGF等细胞因子表达，起到改善预后的效果，值得进一步研究和使用。

Abstract

Objective:

To discuss the effect of Feiyiliu mixture as an adjuvant method for chemotherapy and immune support on progression-free survival (PFS) and survival rate of patients with Ⅲb and Ⅳ stage squamous cell carcinoma of lung (SQCC)

and to investigate its intervention effect on tumor markers and cytokines in peripheral blood.

Method:

One hundred and thirty-two patients were randomly divided into control group (66 cases) and observation group (66 cases) by random number table. Patients in control group received programme of gemcitabine hydrochloride combined with cisplatin (alternative paclitaxel combined with cisplatin) and they also got thymopolypeptides for injection

while the patients in observation group received Feiyiliu mixture

with a treatment course of 4 cycles in both groups. PFS and 12 months' survival rate were recorded during follow-up. Scores of European quality of life collaboration cancer core scale (EORTC QLQ-C30) were graded before and after treatment. Levels of CD3

CD4

CD8

CD4

/CD8

cytokeratin 19 fragment 21-1 (CYFRA21-1)

squamous cell carcinoma antigen (SCC)

carbohydrate antigen 125 (CA125)

vascular endothelial growth factor (VEGF)

matrix metalloproteinase-2 (MMP-2) and MMP-9 were detected

and size of solid tumor was evaluated before and after treatment.

Result:

Clinical remission rate of solid tumor was (35/66)53.03% in observation group

higher than(23/66) 34.85% in control group (

=4.286

0.05). PFS in observation group was 9.8 months (95% CI

4.58-22.37)

more than 5.7 months in control group (95% CI

4.69-20.41) (

0.05). 12 months’ survival rate was 45.45% (30/36) in observation group

more than 27.27% (18/48) in control group (

=4.714

0.05). Scores of physical function

social function and overall quality of life in observation group were higher than those in control group (

0.01)

and scores of fatigue

nausea and vomiting

shortness of breath

loss of appetite

constipation and diarrhea were lower than those in control group (

0.01). Levels of CD3

CD4

and CD4

/CD8

in observation group were higher than those in control group (

0.05)

while levels of CD8

CYFRA21-1

SCC

CA125

VEGF

MMP-2 and MMP-9 were lower than those in control group (

0.01).

Conclusion:

Adjuvant Feiyiliu mixture combined with chemotherapy and immune support can prolong PFS

improve survival rate

stabilize immune function

improve quality of life

inhibit the expression of cytokines such as CYFRA21-1 and vascular endothelial growth factor

and improve prognosis for patients with Ⅲb and Ⅳ stage SQCC. Therefore

it is worth further study and use

关键词

Keywords

references

中华人民共和国国家卫生健康委员会．原发性肺癌诊疗规范(2018年版) [J]．肿瘤综合治疗电子杂志， 2019 ， 5 ( 3 )： 100 - 120 .

T CUFER , T OVCARICEK , O′BRIEN , et al . Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years [J]. Eur J Cancer , 2013 , 49 ( 6 )： 1216 - 1225 .

刘欢，李高峰．肺鳞癌的个体化治疗进展 [J]．现代肿瘤医学， 2019 ， 27 ( 15 )： 2771 - 2775 .

韩荣龙，周家明，胡陵静．癌康宁合剂对晚期非小细胞肺癌化疗后患者维持治疗的临床评价 [J]．中国实验方剂学杂志， 2018 ， 24 ( 19 )： 201 - 206 .

刘思远，李志鹏，郑心．肺抑瘤合剂联合AP化疗方案治疗非小细胞肺癌临床疗效观察 [J]．中国实验方剂学杂志， 2018 ， 24 ( 3 )： 185 - 190 .

曹玉风，宋海燕，孙庆兰，等．肺抑瘤合剂对A549裸鼠移植瘤生长抑制的实验研究 [J]．山东中医杂志， 2016 ， 35 ( 10 )： 901 - 904 .

赵粤 . 肺抑瘤合剂治疗Ⅲb，Ⅳ期肺腺癌的临床研究 [D]．济南：山东中医药大学， 2012 .

支修益，石远凯，于金明，等．中国原发性肺癌诊疗规范(2015年版) [J]．中华肿瘤杂志， 2015 ， 37 ( 1 )： 67 - 78 .

孟琼，万崇华，罗家洪．癌症患者生活质量测定量数EORTC QLQ-C3D的应用概况 [J]．国外医学：社会医学分册， 2004 ， 21 ( 4 )： 147 - 150 .

姜晶，孙秀威，朱锦红，等．肺鳞状细胞癌的遗传学特点及靶向治疗进展 [J]．中国肺癌杂志， 2015 ， 18 ( 3 )： 172 - 178 .

张莹，郭其森，张初峰，等．紫杉醇脂质体联合顺铂与吉西他滨联合顺铂一线治疗晚期肺鳞癌患者的疗效比较 [J]．中国肿瘤临床与康复， 2019 ， 26 ( 4 )： 429 - 432 .

左武琪，胡梦迪，丁晨曦，等．徐荷芬从气阴论治非小细胞肺癌经验撷菁 [J]．江苏中医药， 2018 ， 50 ( 12 )： 13 - 15 .

刘嘉湘．扶正治癌　融汇中西　继承创新 [J]．中国中西医结合杂志， 2019 ， 39 ( 1 )： 10 - 12 .

刘滔，王春茂，文峰，等．奥沙利铂联合胸腺肽胸腔内灌注治疗恶性胸腔积液的疗效及对老年肺癌病人免疫功能的影响 [J]．实用老年医学， 2018 ， 32 ( 3 )： 252 - 255 .

杜军华，乔洪源，尹宜发．血清CEA，CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响 [J]．肿瘤防治研究， 2016 ， 43 ( 2 )： 137 - 140 .

K OKAMURA , K TAKAYAMA , M IZUMI , et al . Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer [J]. Lung Cancer , 2013 , 80 ( 1 )： 45 - 49 .

陈一超，辇伟奇，冉静，等．肿瘤标志物联合检测对肺癌诊断、病理分型和临床分期的临床价值 [J]．国际检验医学杂志， 2018 ， 39 ( 1 )： 32 - 37 .

王堃，何娜萍，吴琼，等．血管内皮生长因子在肺癌中的临床应用价值 [J]．检验医学， 2016 ， 31 ( 9 )： 765 - 769 .

薛慧君，方圆，杨娟利，等．非小细胞肺癌组织MMP-2，MMP-9的表达与组织学类型及临床分期的关系 [J]．现代生物医学进展， 2018 ， 18 ( 20 )： 3870 - 3873 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Modified Qingzao Jiufei Tang on Quality of Life and Survival Period of Patients with Non-small Cell Lung Cancer

Effect of Dingkundan in Adjuvant Treatment of Patients with Radiotherapy and Chemotherapy After Endometrial Carcinoma Operation

Fuzheng Huadu Decoction Maintenance Therapy in Advanced Non Small Cell Lung Cancer after Chemotherapy in 43 Cases

Clinical Efficacy of Feiyiliu Mixture Combined with AP Chemotherapy Regimen in Treatment of Non-small Cell Lung Cancer

Influence of Maintenance Treatment of Traditional Chinese Medicine on Quality of Life and Survival Rate in Patients with Advanced Primary Hepatocarcinoma

Related Author

GU Fang-hong

ZHOU Jian-wei

XIE Li-fang

Si-ying PAN

Dan ZHANG

Xiu-fen WANG

Li TIAN

Yan-jie SUN

Related Institution

Qingpu Branch, Zhongshan Hospital Affiliated to Fudan University

Zhengzhou Shuqing Medical College

Henan People's Hospital

The Third Affiliated Hospital of Henan University of Chinese Medicine

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰